SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM Integrated Shipping Services is trending as Hapag-Lloyd confirmed a signed agreement to acquire the company for $35 per share, representing a significant premium, following ZIM's board rejecting a lower management-led bid and entertaining multiple strategic offers. The community is actively debating the deal's finality, potential for a short squeeze, and the possibility of continued dividends or even a higher offer given geopolitical complexities and ZIM's perceived undervaluation.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending with the community highly anticipating imminent topline Phase 3 superiority data for its wet AMD treatment, Axpaxli, which many believe will trigger a significant stock surge and intensified speculation of a sweetened acquisition offer from Sanofi.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Infleqtion Inc. - Ordinary Shares - Class A

Churchill Capital Corp X 

Infleqtion (formerly CCCX) is garnering immense investor excitement ahead of its NYSE debut under the ticker INFQ, driven by a highly successful merger with minimal redemptions, a landmark NASA contract, and community sentiment touting its undervalued position as a leader in quantum technology.

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge. It operates through the following segments: Healthcare and Non-Healthcare. The Healthcare segment develops, manufactures, and markets a variety of noninvasive monitoring technologies and hospital automation solutions and therapeutics. The Non-Healthcare segment designs, develops, manufactures, markets and sells a broad portfolio of premium, high-performance audio products and services. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Masimo Corp

A significant patent infringement win against Apple regarding blood-oxygen monitoring technology in Apple Watches and a reinstated import ban are driving Masimo's conversation. This positive legal development contrasts with recent substantially lowered preliminary revenue guidance and an activist investor's ongoing push for strategic changes and board representation, creating divided community sentiment.

Corsair Gaming, Inc. designs and supplies hardware components for personal computers. It operates through the Gamer and Creator Peripherals, and Gaming Components and Systems segments. The Gamer and Creator Peripherals segment offers gaming keyboards, mice, headsets, controllers, and gaming gear including capture cards, Stream Decks, USB microphones, studio accessories, and EpocCam software, as well as coaching and training services. The Gaming Components and Systems segment focuses on creating power supply units, or PSUs, cooling solutions, computer cases, DRAM modules, prebuilt, and custom-built gaming PCs. The company was founded by Andrew J. Paul in 1994 and is headquartered in Milpitas, CA.

Corsair Gaming Inc

Corsair Gaming is trending following robust earnings, a newly approved $50 million share repurchase program, and a notable spike in short borrowing rates. The community is actively discussing a potential short squeeze, highlighting the company's strong performance and its advantageous position in the memory market due to rising RAM prices and reduced competition.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is drawing significant attention as its stock sits at multi-year lows, driven by widespread investor frustration over a recent CFO change, perceived management silence, and broader ad-tech sector pressures. Community sentiment is sharply polarized between those warning of further declines due to valuation concerns and others seeing a generational buying opportunity ahead of its upcoming earnings report.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is drawing intense investor attention ahead of upcoming Phase 3 clinical data for its COMP360 psilocybin therapy in treatment-resistant depression, with the community widely anticipating the critical MADRS score to determine the stock's immediate future. This pivotal readout is seen as a major catalyst for the company and the nascent psychedelic therapeutics sector, positioning CMPS as a potential first-mover in a field many believe is on the cusp of significant regulatory and commercial breakthroughs.

SSR Mining, Inc. is a gold company with assets located in four jurisdictions: the USA, Turkiye, Canada, and Argentina, which engages in the operation, acquisition, exploration and development of precious metal resource properties. The firm produces gold ore as well as copper, silver, lead and zinc concentrates. It operates through the following business segments: Copler, Marigold, Seabee and Puna. The Copler, Marigold, Seabee, and Puna segments represent its four operating mine sites. The company was founded on December 11, 1946 and is headquartered in Denver, CO.

SSR Mining Inc

SSR Mining is gaining traction ahead of its highly anticipated earnings, with the community discussing expectations for a significant EPS increase driven by robust gold prices and strategic mine contributions, despite lingering concerns over the Copler mine incident.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as recent softer inflation data, flat retail sales, and rising jobless claims intensify community expectations for earlier Fed rate cuts, driving a rally amid a 'flight to safety' narrative. However, fierce debate persists over the reliability of economic data and the long-term trajectory for bond yields.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Bitcoin is trending as recent ETF outflows and a significant price correction ignite intense community debate; while many voice short-term bearish concerns, others view the downturn as a strategic accumulation phase before a potential rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioNexus Gene Lab Corp. (BGLC) announced on Wednesday that it has entered into definitive agreements with Asia-based firms Fidelion Diagnostics Pte. and Tongshu Biotechnology, among other parties, to commercialize VitaGuard in Southeast Asia.VitaGuard is a high-fidelity, tumor-naïve liquid biopsy platform for minimal residual disease, meaning it detects tiny fragments of tumor DNA without requiring a tumor tissue sample. Minimal residual disease (MRD) is a small number of cancer cells that remain in the body during or after treatment, which are undetectable by standard methods.<h2 class="st-heading-2">Transaction Terms And Details</h2>China-headquartered Tongshu Gene is the original developer of the VitaGuard technology. The firm serves as the research and development, as well as manufacturing partner of Singapore-based Fidelion.The partnership <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/12/3186213/0/en/BioNexus-Gene-Lab-Corp-Nasdaq-BGLC-Announces-Strategic-Agreements-with-Fidelion-Diagnostics-for-Southeast-Asia-MRD-Commercialization.html">aims</a> to support the planned commercialization of MRD testing in Southeast Asia with an initial focus in Singapore and Malaysia.Under the agreement, BGLC will receive new Fidelion shares equal to at least 15 % of Fidelion’s fully diluted share capital, and Fidelion will receive newly issued, restricted BGLC shares equal to 19.9% of BGLC’s pre-money outstanding shares. The BGLC share issuance will be made in a private transaction, the company said.The completion of the transaction is conditioned upon an Intellectual Property License Agreement granting BGLC exclusive commercialization rights across the Association of Southeast Asian Nations.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BGLC">BGLC stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘extremely low’ to ‘extremely high’ levels.BGLC stock is up 68% this year and approximately 42% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/toyota-commits-up-to-10-billion-additional-investment-in-us-over-five-years/cLPI6vHREdJ">Toyota Commits Up To $10B Additional Investments In US Over Five Years</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

BGLC Stock Tumbled Over 13% Today: Why Is VitaGuard Commercialization Agreement Drawing Investor Attention?

The partnership aims to support the planned commercialization of minimal residual disease testing in Southeast Asia.

Equity

The partnership aims to support the planned commercialization of minimal residual disease testing in Southeast Asia.


BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. It is also involved in the development of liquid biopsy tests for the early detection of biomarkers that are linked to diseases. It operates through the BioNexus Malaysia and Chemrex segments. The company was founded by Liew Choong-Chin on May 12, 2017 and is headquartered in Kuala Lumpur, Malaysia.

BioNexus Gene Lab Corp

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

BGLC
BioNexus Gene Lab Corp

Feed

News

Sentiment

Fundamentals

Info

Latest BGLC News

BGLCBioNexus Gene Lab Corp